Clinical and economic consequences of pharmacogenetic-guided dosing of warfarin
Patients using warfarin for oral anticoagulant therapy need to be frequently monitored because of warfarins narrow therapeutic range and the large variation in dose requirements among patients. Patients receiving the wrong dose have an increased risk of bleeding or thromboembolic events. The required dose is influenced by environmental factors, such as gender, age, diet and concomitant medication, as well as genetic factors. Pharmacogenetic testing prior to warfarin initiation might improve dosing accuracy and, therefore, safety and efficacy of warfarin treatment. Meckley et al. studied the clinical consequences and costs of genotyping before warfarin treatment. The results of their study suggest that pharmacogenetic-guided dosing of patients initiating warfarin could improve health (quality-adjusted life-years) but at a high cost per quality-adjusted life-year gained. Owing to the inevitable assumptions that have to be made in all cost-effectiveness models, great uncertainty remains regarding the cost-effectiveness of pharmacogenetic-guided warfarin dosing.
|Keywords||CYP2C9, VKORC1, economics, pharmacogenetics, warfarin|
|Persistent URL||dx.doi.org/10.1586/erp.10.42, hdl.handle.net/1765/21095|
Verhoef, T.I, Schalekamp, T, Redekop, W.K, de Boer, A, & Maitland-van der Zee, A-H. (2010). Clinical and economic consequences of pharmacogenetic-guided dosing of warfarin. Expert Review of Pharmacoeconomics & Outcomes Research, 10(4), 375–378. doi:10.1586/erp.10.42